<DOC>
	<DOC>NCT00935675</DOC>
	<brief_summary>Evaluation of the effectiveness of escitalopram on depressive symptoms after 3 months in patients with head and neck squamous cell carcinomas (oral cavity, larynx, oropharynx and hypopharynx) and with an HADS total score &gt; 11</brief_summary>
	<brief_title>Double-blind, Placebo-controlled, Randomized Study of the Effectiveness of Escitalopram on Emotional Distress of Head and Neck Cancer Patients During Cancer Treatment</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>1. Head and neck squamous cell carcinomas, stage I to IVb 2. Firstline curative cancer therapy : surgery and/or brachytherapy and/or chemotherapy 3. HADS T &gt;11 4. Aged 18 to 75 yo, written consent required 5. OMS&gt;2 1. Palliative care 2. Previous head and neck cancer 3. Bipolar disorder or schizophrenia 4. Severe major depressive disorder (DSMIV TR) 5. Expressed suicidal ideation 6. Severe untreated organic disorder, especially acute infectious disorder 7. ASAT/ALAT &gt; 3N 8. Clearance of creatinin &lt; 30 ml/mn 9. Hyponatremia 10. Antecedent of delirium tremens or acute alcohol withdrawal disorder 11. Antecedent of upper gastrointestinal bleeding 12. Antecedent of toxicity or inefficacy of a previous treatment with escitalopram 13. Unauthorized treatments : Antidepressant or antiepileptic (clonazepam authorized) Hypnotic except zolpidem Anxiolytic except clonazepam, clorazepate or diazepam bupropion or varenicline 14. Pregnancy or lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Patients with head and neck squamous cell carcinomas</keyword>
	<keyword>head and neck squamous cell carcinomas</keyword>
</DOC>